- Home
- GOSS vs AOMR Comparison
GOSS vs AOMR Comparison
Compare GOSS & AOMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- AOMR
- Stock Information
- Founded
- GOSS 2015
- AOMR 2018
- Country
- GOSS United States
- AOMR United States
- Employees
- GOSS N/A
- AOMR N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- AOMR Real Estate Investment Trusts
- Sector
- GOSS Health Care
- AOMR Real Estate
- Exchange
- GOSS Nasdaq
- AOMR Nasdaq
- Market Cap
- GOSS 262.5M
- AOMR 237.8M
- IPO Year
- GOSS 2019
- AOMR 2021
- Fundamental
- Price
- GOSS $1.23
- AOMR $9.41
- Analyst Decision
- GOSS Strong Buy
- AOMR Strong Buy
- Analyst Count
- GOSS 4
- AOMR 6
- Target Price
- GOSS $7.75
- AOMR $11.75
- AVG Volume (30 Days)
- GOSS 2.6M
- AOMR 96.1K
- Earning Date
- GOSS 08-11-2025
- AOMR 08-05-2025
- Dividend Yield
- GOSS N/A
- AOMR 13.59%
- EPS Growth
- GOSS N/A
- AOMR N/A
- EPS
- GOSS N/A
- AOMR 1.51
- Revenue
- GOSS $124,590,000.00
- AOMR $57,147,000.00
- Revenue This Year
- GOSS N/A
- AOMR N/A
- Revenue Next Year
- GOSS $91.14
- AOMR $10.94
- P/E Ratio
- GOSS N/A
- AOMR $6.23
- Revenue Growth
- GOSS N/A
- AOMR N/A
- 52 Week Low
- GOSS $0.66
- AOMR $7.36
- 52 Week High
- GOSS $1.55
- AOMR $13.32
- Technical
- Relative Strength Index (RSI)
- GOSS 54.09
- AOMR 53.86
- Support Level
- GOSS $1.25
- AOMR $9.11
- Resistance Level
- GOSS $1.44
- AOMR $9.35
- Average True Range (ATR)
- GOSS 0.10
- AOMR 0.14
- MACD
- GOSS -0.00
- AOMR 0.02
- Stochastic Oscillator
- GOSS 41.67
- AOMR 93.02
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.